Utilization Patterns of Qsymia (Phentermine/Topiramate)

Basic Details
Date Posted
Tuesday, August 6, 2019
Status
Complete
Medical Product
phentermine HCl
phentermine/topiramate
Qsymia
topiramate
Description

The goal of this request was to estimate the number of incident users of Qsymia (combination product of phentermine and topiramate), phentermine, topiramate, and concomitant phentermine and topiramate in the Sentinel Distributed Database (SDD). Data from September 17, 2012 to April 30, 2017 from 16 Data Partners contributing to the SDD were included in these reports. This request was distributed on August 17, 2017.

Report 1 characterizes the uptake and utilization of Qsymia, phentermine, and topiramate, including the distribution of days supply, length of treatment episodes, and time to drug initiation.

Report 2 estimates the number of incident users of these drugs along with concomitant phentermine and topiramate, with additional estimates among individuals with a history of either epilepsy or seizures, with a history of migraines, and with no history of those conditions. 

Additional Details
FDA Center
CDER
Time Period
September 17, 2012 - April 30, 2017
Study Type
Modular Program
Assessment Type
Exploratory Analyses
Population / Cohort
Individuals 18 years of age and older
Data Sources
Sentinel Distributed Database (SDD)